Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis.
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.
This new catheter-based device for lymphatic drainage showed early potential to be an effective treatment option for acute decompensated heart failure.
The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
MRI exams are crucial for investigating fetal abnormalities, but past concerns have been expressed about whether the modality could affect intrauterine growth.
In addition to more traditional presentations, this year's meeting will also include "Rapid Fire" sessions designed to pack a lot of late-breaking data into a relatively small amount of time.
The findings, based on data from more than 800 TAVR patients, suggest that skipping OAC medications for a small amount of time could make a big impact.
“No clear recommendation currently exists in U.S. or European guidelines for performing PCI in addition to TAVR,” researchers wrote. The group hoped its study could provide some clarity.
According to new MODULAR ATP data, the leadless system was associated with a high success rate and few complications. Boston Scientific plans on seeking FDA approval in 2025.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
